Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$60.9M Sell
2,207,594
-289,422
-12% -$6.39M 0.05% 254
2026
Q1
$36.5M Buy
+2,497,016
New +$36.6M 0.04% 294
2025
Q1
Sell
-42,937
Closed -$1.02M 759
2024
Q4
$1.02M Sell
42,937
-16,683
-28% -$466K ﹤0.01% 569
2024
Q3
$1.67M Sell
59,620
-24,200
-29% -$683K ﹤0.01% 539
2024
Q2
$2.19M Buy
83,820
+41,294
+97% +$859K ﹤0.01% 495
2024
Q1
$930K Buy
42,526
+25,519
+150% +$547K ﹤0.01% 580
2023
Q4
$396K Sell
17,007
-18,103
-52% -$364K ﹤0.01% 638
2023
Q3
$693K Buy
35,110
+14,245
+68% +$281K ﹤0.01% 598
2023
Q2
$473K Buy
+20,865
New +$420K ﹤0.01% 629

Other funds holding RXO

Boston Partners's RXO Position: Q2 2026 in Review

Boston Partners reduced its RXO (RXO) stake by 12% in Q2 2026, selling an estimated $6.39M and leaving 2,207,594 shares worth $60.9M. The position accounts for 0.05% of the portfolio, ranked #254.

Boston Partners first reported a position in RXO in Q2 2023 and has held it in 9 quarters since. 303 funds tracked by Wall St. Rank hold RXO as of Q2 2026.

  • Boston Partners held 2,207,594 shares of RXO worth $60.9M as of Q2 2026.
  • Boston Partners sold 289,422 RXO shares in Q2 2026, an estimated $6.39M.
  • RXO made up 0.05% of Boston Partners's portfolio in Q2 2026, its #254 holding.
  • Boston Partners first reported a position in RXO in Q2 2023 and has held it in 9 quarters since.
  • 303 funds tracked by Wall St. Rank held RXO as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.